Article Text

Download PDFPDF

6ER-027 Blood cytokine evaluation in patients with intravitreal ranibizumab for neovascular age-related macular degeneration
  1. L García-Quintanilla1,
  2. P Almuiña-Varela2,
  3. C Mondelo-García1,
  4. M Gil-Martínez2,
  5. MJ Abraldes2,
  6. MJ Rodríguez-Cid2,
  7. MI Fernández-Rodríguez2,
  8. A Castro-Balado1,
  9. I Zarra-Ferro1,
  10. A Fernández-Ferreiro1
  1. 1Área Sanitaria Santiago de Compostela e Barbanza, Pharmacy, Santiago de Compostela, Spain
  2. 2Área Sanitaria Santiago de Compostela e Barbanza, Ophthalmology, Santiago de Compostela, Spain


Background and importance Inflammation is involved in the development and pathogenesis of age-related macular degeneration (n-AMD) although the roles that the inflammation-related cytokines play in it are not yet defined as some of them are pro-angiogenic. Local and systemic inflammatory molecules are being proposed as potential biomarkers of n-AMD progression.

Aim and objectives The aim of this study was to evaluate cytokine values after the ranibizumab loading phase in patients with n-AMD.

Material and methods Prospective, observational study of n-AMD patients with criteria to initiate treatment with ranibizumab. A blood test was performed at the initial visit (prior to the first administration of ranibizumab) and after finishing the loading doses (4 months). Demographic, clinical and blood analytical parameters (C-reactive protein (CRP), β2-microglobulin, tumour necrosis factor (TNF), interleukins rIL-2, IL-5, IL-6, IL-8 and IL-10) were obtained through electronic medical records. Statistical analysis was performed using Student’s t-test (SPSS Statistics V.26, IBM Inc.).

Results A total of 45 patients were included (40% men). Mean age was 80±8 years. 41 patients responded to treatment (14 partially), 2 did not respond to treatment and 2 did not finished the loading phase. Visual acuity obtained a statistically significant improvement in responder patients (EDTRS: 56±17 vs 63±16, p<0.002).

In responders, changes in cytokine serum levels did not reach statistically significant differences between the initial visit and after the loading phase (p>0.05): TNF (8.97±2.78 vs 9.04±3.75 pg/mL), CRP (0.323±0.387 vs 0.324±0.332 mg/dL), β2-microglobulin (2.77±0.92 vs 2.85±0.95 mg/L), IL-6 (6.6±3.3 vs 6.5±6.1 pg/mL), rIL-2 (516.0±213.9 vs 529.6±224.9 U/mL). Although IL-8 (51.46±66.5 vs 85.95±115.1 pg/mL) showed an increase after the loading phase, it did not reach statistical significance (p=0.088). IL-5 and IL-10 remained undetected over time in both responders and non-responder patients.

Conclusion and relevance Changes at the end of the loading phase in IL-6 and IL-8 have been described previously with the administration of anti-angiogenics. In our case, no differences were detected, probably due to the low sample size. More studies will be necessary to determine the prognostic potential of the change in systemic cytokines as a response parameter in patients treated with anti-angiogenics in AMD.

References and/or acknowledgements This study was partially supported by Health Institute Carlos III and co-financed by FEDER (PI17/00940, RETICS Oftared, RD16/0008/0003, RD12/0034/0017)

Conflict of Interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.